Cary Street Partners Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Cary Street Partners Asset Management's VRTX Position: Q4 2022 in Review
Cary Street Partners Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 37 shares — an estimated $11K sold.
Cary Street Partners Asset Management first reported a position in VRTX in Q3 2022 and held it in 1 quarter. The position peaked at $11K in Q3 2022. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.
- Cary Street Partners Asset Management reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Cary Street Partners Asset Management sold 37 Vertex Pharmaceuticals shares in Q4 2022, an estimated $11K.
- Cary Street Partners Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2022 and held it in 1 quarter.
- Cary Street Partners Asset Management's Vertex Pharmaceuticals position peaked at $11K in Q3 2022.
- 1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.
Based on Cary Street Partners Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.